Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors

• Status: Completed
• Trial end date: 2000-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase I trial to study the effectiveness of paclitaxel plus topotecan in treating patients who have solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Albumin-Bound Paclitaxel; Paclitaxel; Topotecan

Criteria

DISEASE CHARACTERISTICS:

• Histologically proven solid tumor

• Measurable or evaluable disease

• Measurable disease defined as tumor outside prior radiotherapy fields and reproducibly measurable in 2 dimensions on physical exam, x-ray, CT, or MRI

PATIENT CHARACTERISTICS:

• Age: 18 and over

• Performance status: 0 or 1

• Life expectancy: At least 12 weeks

• WBC at least 4,000/mm3

• Platelet count at least 100,000/mm3

• Bilirubin no greater than 1.5 mg/dL

• AST less than 3 times normal

• Alkaline phosphatase less than 3 times normal

• Creatinine no greater than 1.5 mg/dL

• No poorly controlled angina

• No history of congestive heart failure

• No myocardial infarction within the past 6 months

• Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

• No concurrent prophylactic hematopoietic growth factors

• No concurrent medications altering cardiac conduction